TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01270035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: To increase the ADA dose from 40 mg eow to 80 mg eow
Study: NCT02505958

Intervention type: OTHER
Group type: OTHER
Intervention: high caloric intake
Description: Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing \~ 6000 Kcal/24 h.

Intervention type: OTHER
Group type: OTHER
Intervention: reduced caloric intake
Description: On days 5 and 6, volunteers will received 3 meals (\~333 calories each) totaling \~ 1,000 calories/24 hours.
Study: NCT04773223

Intervention type: PROCEDURE
Intervention: Open surgery and complex EVAR due to AAA
Description: There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)

Intervention type: PROCEDURE
Intervention: Open surgery and complex EVAR due to AAA
Description: There will be two cohorts:~1. Patient undergoing open surgery~2. Patients undergoing complex endovascular repair (fenestrated, chimney, etc.)
Study: NCT03259958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Donepezil Hydrochloride Transdermal Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept Tablet
Study: NCT01819714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-sensory supportive care
Description: The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design.
Study: NCT04768140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bobath treatment approach
Description: scapulothoracic mobilization exercise, reaching in different directions in the supine position and upper extremity weight transfer exercise.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: range of motion, stretching, strengthening exercises, electrotherapy, thermotherapy, balance and mobility exercises and exercises for daily living activities.
Study: NCT04685993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPCN 1144
Description: Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).
Study: NCT01065818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro-L-Thymidine
Description: 4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
Study: NCT04387123

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginoscopy
Description: Vaginoscopic examination and possible operative endoscopic management

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginoscopy
Description: Vaginoscopic examination and possible operative endoscopic management
Study: NCT01447407

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3 vaccine with alum IM
Description: One dose administered IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3 vaccine without alum IM
Description: One dose administered IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with alum IM
Description: One dose administered ID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NDV-3 vaccine without alum ID
Description: One dose administered ID
Study: NCT02420535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediately Receive Tool

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Month Delay
Study: NCT02464124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: • Nitazoxanide dosing: 500 mg tablets twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: • Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: • Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
Study: NCT04023396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Study: NCT03388424

Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis

Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis

Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis

Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis

Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis

Intervention type: DIAGNOSTIC_TEST
Intervention: quantification of microbiota
Description: For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
Study: NCT04811157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test product
Description: 200 g/day of unsweetened yogurt supplemented with a dietary fiber blend

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control product
Description: 200 g/day of unsweetened yogurt
Study: NCT02412124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Complete W2W mentoring program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete the FACT-G

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete the W2W Patient Survey
Study: NCT02739217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4050
Description: Four 200 mg capsules (800 mg total) administered orally, once daily.
Study: NCT02515630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMB
Description: Momelotinib (MMB) tablet administered orally once daily
Study: NCT04542980

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV2 Autoantibody detection
Description: Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2
Study: NCT03092752

Intervention type: DRUG
Intervention: oral antidiabetic drugs
Description: OADs usage conditions and dose selection in T2DM patients
Study: NCT02311829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone follow-up device
Description: For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
Study: NCT02646969

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula regimen 1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula regimen 2
Study: NCT00488423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance test, Hyperglycemic clamp
Description: Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Tolerance test, Hyperglycemic clamp
Description: Subjects undergo a standard mixed meal tolerance test \& hyperglycemic clamp to assess insulin secretion \& sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp \& mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting \& specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass \& gastric banding.
Study: NCT01769677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Study: NCT04064112

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: S-BLR
Description: Surgery of slanted bilateral LR recession for CI-IXT patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: C-BLR
Description: Surgery of conventional bilateral lateral rectus recession for CI-IXT patients
Study: NCT04073719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
Study: NCT03778554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Eligible patients randomized to receive long-term therapy with oral beta-blockade
Study: NCT04073719

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Cider Vinegar
Description: Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Other Beverage
Description: To what degree do other high citrate beverages impact urinary citrate output.
Study: NCT00412841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg vs placebo 40mg daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI, Venipuncture
Description: MRIs done baseline, four and nine months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI, Venipuncture
Description: MRIs done baseline, four and nine months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical to atorvastatin 40mg
Study: NCT01015326

Intervention type: OTHER
Intervention: Questionnaire
Description: Administered questionnaire

Intervention type: OTHER
Intervention: Questionnaire
Description: Administered questionnaire
Study: NCT04702152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted memory reactivation (sounds)
Description: I will unobtrusively and repeatedly present learning-related sounds during sleep using speakers. This method was shown to improve memory in various tasks. The sounds will be presented several seconds apart and the volume will be so adjusted as not to disturb the participant's sleep. The sounds will be presented during non-rapid eye movement sleep (sleep stage 2 and slow wave sleep). The sounds presented will be non-congruently related to the scenes in the previous learning task. This manipulation is within-subject - all participants will get it, but different specific sounds will be presented for each individual participant.
Study: NCT03262077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Irradiation with low-level laser for 1, 3, and 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Irradiation with low-level laser for 1, 3, and 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Irradiation with low-level laser for 1, 3, and 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue Oral Product
Description: Irradiation with low-level laser for 1, 3, and 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue Oral Product
Description: Irradiation with low-level laser for 1, 3, and 5 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue Oral Product
Description: Irradiation with low-level laser for 1, 3, and 5 min
Study: NCT00941850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upgrade to triple ventricular site CRT
Description: Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
Study: NCT03583658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambroxol BIH1526
Description: Pharmaceutical form: lozenges Route of administration: oromucosal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: lozenges Route of administration: oromucosal
Study: NCT02433847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride
Study: NCT02702089

Intervention type: PROCEDURE
Intervention: Rectal cancer surgery
Description: Rectal cancer resection

Intervention type: PROCEDURE
Intervention: Rectal cancer surgery
Description: Rectal cancer resection
Study: NCT01586052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 250 IU/kg, Twice a week for 4 weeks
Study: NCT00752089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF/ KNO3/isopentane Dentifrice
Description: Experimental toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF/KNO3 Dentifrice
Description: Experimental toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF Dentifrice
Description: Active comparator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dentifrice
Description: Placebo comparator
Study: NCT02025192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered twice per day, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered twice per day, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Administered twice per day, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m\^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
Study: NCT03087734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of new model of bar with oblique stabilizers
Description: Implantation of new model of bar with oblique stabilizers

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of regular bar with perpendicular stabilizers
Description: Implantation of regular bar with perpendicular stabilizers
Study: NCT03200548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxing acupressure plus usual care
Description: Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Negative control group. Participants are asked to carry on with their usual management practices and habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulating acupressure plus usual care
Description: Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure plus usual care
Description: Positive control group. Chosen pressure points are not known to be effective.
Study: NCT03228641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micro-excisional skin removal with coring needle
Study: NCT03098680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine Hydrochloride
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine Hydrochloride
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: see arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: see arm/group descriptions